Min Li

US Patent:

7029918, Apr 18, 2006

Filed:

Jan 25, 2002

Appl. No.:

10/057762

Inventors:

Min Li - Ringoes NJ, US
Robert S. Wu - West Orange NJ, US
Jane S. C. Tsai - Indianapolis IN, US

Assignee:

Roche Diagnostics Operations, Inc. - Indianapolis IN

International Classification:

G01N 33/548
G01N 30/90
C07D 243/24

US Classification:

436 8, 436161, 436530, 436815, 540507, 540510

Abstract:

A water-soluble reference standard is useful for immunoassays of a lipophilic drugs. The reference standard is a compound of formula (I):G-(L)—Y;  (I)where G is a lipophilic drug; L is a linker which is an alkyl group or heteroalkyl group containing from 1 to 20 carbon atoms; n is 0 or 1; and Y is a water-solubilizing group such as —SO, —NR—SO, —P(═O)(OH)(O), or —O—P(═O)(OH)(O); where R is H or an alkyl group of 1 to 10 carbon atoms.

US Patent:

20020172968, Nov 21, 2002

Filed:

Feb 19, 2002

Appl. No.:

10/080376

Inventors:

Hongxiang Liu - Monrovia CA, US
Bassil Dahiyat - Altadena CA, US
Min Li - Lutherville MD, US

International Classification:

C12Q001/68
C07H021/04

US Classification:

435/006000, 536/024300

Abstract:

The present invention is directed to the formation of protein arrays through the use of nucleic acid/protein (NAP) conjugates, which allow the covalent attachment of proteins and the nucleic acids encoding them. By using vectors that include capture sequences that will hybridize to capture probes on a nucleic acid array, the NAP conjugates including the proteins of interest are arrayed and used in a wide variety of applications.

US Patent:

20030068649, Apr 10, 2003

Filed:

Mar 12, 2002

Appl. No.:

10/097100

Inventors:

Stephen Doberstein - Pasadena CA, US
Cheng Jin - San Diego CA, US
Min Li - Lutherville MD, US
Christian Melander - Monrovia CA, US

International Classification:

C12Q001/68
G01N033/53
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/007100, 435/006000, 435/069700, 435/320100, 435/325000, 536/023100

Abstract:

This invention pertains to genetic libraries encoding enzyme fusion proteins and methods of use to identify a nucleic acid of interest.

US Patent:

20030124537, Jul 3, 2003

Filed:

Dec 14, 2001

Appl. No.:

10/023208

Inventors:

Yuan-Chin Liu - Arcadia CA, US
Min Li - Lutherville MD, US

International Classification:

C12Q001/68
C12N009/22
C12N001/21
C12N015/74

US Classification:

435/006000, 435/199000, 435/252300, 435/320100

Abstract:

The invention relates to methods and compositions for the construction of prokaryotic libraries expressing candidate proteins and the use of these libraries to identify candidate proteins and the nucleic acids encoding them.

US Patent:

20130274138, Oct 17, 2013

Filed:

Jun 7, 2013

Appl. No.:

13/913077

Inventors:

Stephen Forman - Duarte CA, US
Jerald P. Radich - Seattle WA, US
Liang Li - Duarte CA, US
Min Li - Duarte CA, US
Lue Ping Zhao - Seattle WA, US

International Classification:

C12Q 1/68

US Classification:

506 9, 506 16

Abstract:

In one embodiment, a gene expression signature for predicting risk of developing therapy-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) after autologous hematopoietic cell transplantation (aHCT) is provided. In another embodiment, a method for predicting a risk for development of t-MDS/AML after aHCT is provided. Such a method may include providing a biological sample that contains CD34 cells from a subject; detecting a test expression level of a set of two or more genes of a gene expression signature; comparing the test expression level of a set of corresponding training expression levels that include a training case expression level and a training control expression level; and predicting a high risk of developing t-MDS/AML when the test expression level is at or about the training case expression level or predicting a low risk of developing t-MDS/AML when the test expression level is at or about the training control expression level.

US Patent:

20130296245, Nov 7, 2013

Filed:

Nov 14, 2011

Appl. No.:

13/884196

Inventors:

Min Li - Ringoes NJ, US
Hanbin Shan - Shanghai, CN
Yu Huang - Shanghai, CN
Zhedong Yuan - Shanghai, CN
Xiong Yu - Shanghai, CN

International Classification:

C07K 5/02
C07D 205/04
C07D 211/60

US Classification:

514 147, 548533, 514330, 546225, 51421017, 548953, 546208, 548518, 548527, 5462791, 514315

Abstract:

Provided are a compound of formula (I), pharmaceutically acceptable salts thereof, preparation methods and applications thereof for inhibiting thrombin, and applications in the treatment and prevention of thrombin-mediated and thrombin-related diseases.

US Patent:

20220296491, Sep 22, 2022

Filed:

Aug 10, 2020

Appl. No.:

17/632969

Inventors:

- New York NY, US
Min LI - Bridgewater NJ, US
Aixing FAN - Bridgewater NJ, US
Thomas BOYD - Metuchen NJ, US
Melissa MOY - Staten Island NY, US

Assignee:

Colgate-Palmolive Company - New York NY

International Classification:

A61K 8/73
A61K 8/60
A61K 8/67
A61Q 19/10
A61K 8/34
A61K 8/92

Abstract:

Described herein are personal care compositions comprising—inter alia—a gum system comprising a plurality of natural gums; a surfactant system comprising a plurality of alkyl polyglucoside surfactants; and a cosmetically acceptable carrier. Methods of making and using these compositions are also described herein.

US Patent:

20220241162, Aug 4, 2022

Filed:

Apr 7, 2022

Appl. No.:

17/658288

Inventors:

- New York NY, US
Min LI - Bridgewater NJ, US
Thomas BOYD - Metuchen NJ, US
Shyamala PILLAI - Hillsborough NJ, US
Katie TRUONG - Piscataway NJ, US
Laurence DU-THUMM - Princeton NJ, US

Assignee:

Colgate-Palmolive Company - New York NY

International Classification:

A61K 8/34
A61K 8/86
A61Q 15/00
A61Q 17/00
A61K 8/37
A61K 8/41
A61K 8/49
A61K 8/42
A61K 8/20
A61K 8/27

Abstract:

Compositions, such as personal care compositions, and methods for selectively inhibiting the growth of a detrimental bacteria and promoting the growth of a beneficial bacteria are disclosed. The composition may include a base and one or more fatty alcohols. The one or more fatty alcohols may be present in an amount effective to selectively inhibit the growth of at least one detrimental Gram-positive bacteria and promote the growth of at least one beneficial Gram-positive bacteria on skin. The detrimental Gram-positive bacteria may include , and the beneficial Gram-positive bacteria may include